Evidence map›Paper›PMID 32821190›Full record

ArticleClinical Medicine Insights. Oncology2020

Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?

Emanuela Dell'Aquila, Tea Zeppola, Marco Stellato, Francesco Pantano, Mario Scartozzi, Cristina Madaudo, Filippo Pietrantonio, Chiara Cremolini, Giuseppe Aprile, Bruno Vincenzi and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Emanuela Dell'AquilaDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
Tea ZeppolaDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
Marco StellatoDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.ORCID https://orcid.org/0000-0002-0993-7540
Francesco PantanoDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
Mario ScartozziMedical Oncology, University Hospital and University of Cagliari, Cagliari, Italy.
Cristina MadaudoDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
Filippo PietrantonioMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Chiara CremoliniUnit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Giuseppe AprileDepartment of Oncology, San Bortolo General Hospital, Vicenza, Italy.
Bruno VincenziDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
Roberto MorettoUnit of Medical Oncology 2, Department of Translational Research and New Technologies in Medicine and Surgery, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Marco PuzzoniMedical Oncology, University Hospital and University of Cagliari, Cagliari, Italy.
Silvio Ken GarattiniDepartment of Oncology, University Hospital of Udine, Udine, Italy.
Riccardo LobefaroMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.ORCID https://orcid.org/0000-0003-3484-9718
Giuseppe ToniniDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
Daniele SantiniDepartment of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
Università Campus Bio-Medico · ITAzienda Ospedaliera Universitaria Pisana · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITUniversity of Cagliari · ITOspedale San Bortolo · ITUniversity of Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDue to the relative rarity of small bowel adenocarcinoma (SBA), prospective trials, helping to guide therapeutic decisions, are lacking and the optimal therapy for advanced SBA is unknown. The role of targeted agents, such as anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor (VEGF), is unknown. PATIENTS AND

methodsThis is a retrospective multicenter observational study that included patients with metastatic SBA treated with anti-EGFR antibodies (cetuximab or panitumumab) ± chemotherapy in the first (I) or second (II) line.

resultsThirteen patients with metastatic SBA, recruited from 5 Italian referral institutions, were included in the present retrospective analysis. All patients received anti-EGFR inhibitors as a single agent or in association with chemotherapy. More common G2 treatment-related side effects were skin reaction (8 patients, 53.8%), hypomagnesemia (6 patients, 46.2%), and diarrhea (8 patients, 61.5%). Grade 3 diarrhea was observed in only 1 patient. Conjunctivitis was not reported in any patients. Grade 4 toxicity was not reported. In the overall population, median progression-free survival was 5.526 months (95% confidence interval [CI]: 3.684-12.467). Median overall survival was 15.86 months (95% CI: 14.43-24.30). Complete response was observed in 15% of patients, partial response in 39% of patients, stable disease in 23% of patients, and progression disease in 15% of patients.

conclusionsIn this retrospective analysis, anti-EGFR inhibitors showed to be a suitable addendum to chemotherapy in the I and II line, with an excellent tolerance and safety profile both in I and II line.

Indexed as

anti-EGFR inhibitorscetuximabchemotherapypanitumumabSmall bowel adenocarcinomatoxicity

Identifiers

PMID32821190
PMCPMC7412900
OpenAlexW3046990350

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.